MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Financials
Key financial figures for MoonLake Immunotherapeutics Class A Ordinary Shares (Q2 2026).
MoonLake Immunotherapeutics reported revenue of $0.00 for Q2 FY2026. The company posted a net loss of $61.8 million, or -$0.84 per share. Free cash flow for the period was -$55.6 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for MoonLake Immunotherapeutics are on the SentiSense financials page.
- Revenue
- $0
- Net Income
- -$62M
- EPS
- $-0.84
- Total Assets
- $574M
- Operating Cash Flow
- -$56M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $0 | -$62M | -$0.84 | -$56M | |
| Q1 FY2026 | $0 | -$70M | -$0.98 | -$66M | |
| Q4 FY2025 | $0 | -$62M | -$0.93 | -$59M | |
| Q3 FY2025 | $0 | -$70M | -$1.10 | -$45M | |
| Q2 FY2025 | $0 | -$55M | -$0.87 | -$55M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$227M | -$3.53 | -$196M | |
| FY2024 | $0 | -$119M | -$1.89 | -$117M | |
| FY2023 | $0 | -$36M | -$0.73 | -$43M |
Frequently asked questions
What was MoonLake Immunotherapeutics's revenue last quarter?
MoonLake Immunotherapeutics reported revenue of $0.00 for Q2 FY2026.
Is MoonLake Immunotherapeutics profitable?
Not in its most recent reported period. MoonLake Immunotherapeutics reported a net loss of $61.8 million for Q2 FY2026.
How much free cash flow did MoonLake Immunotherapeutics generate?
MoonLake Immunotherapeutics generated free cash flow of -$55.6 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for MoonLake Immunotherapeutics Class A Ordinary Shares on SentiSense, with up to forty quarters and twenty fiscal years of history.